No Photo Available

Last Update

2017-01-26T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Klara Dickinson?

Ms. Klara A. Dickinson

Senior Vice President and Chief Regulatory Officer

Anthera Pharmaceuticals Inc

HQ Phone: (510) 856-5600

Email: k***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Anthera Pharmaceuticals Inc

25801 Industrial Boulevard Suite B

Hayward, California 94545

United States

Company Description

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A ... more

Find other employees at this company (59)

Background Information

Employment History

Senior Director, Drug Safety

Horizon Pharma plc

Education

BS

biology

College of Great Falls

Web References (32 Total References)


Management – Anthera Pharmaceuticals

www.anthera.com [cached]

Klara A. Dickinson - Senior Vice President and Chief Regulatory Officer Ms. Dickinson served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for Hyperion Therapeutics' initial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid for use as a nitrogen-binding agent for chronic management of adult and pediatric patients =2 years of age with urea cycle disorders (UCDs). Prior to Hyperion Therapeutics, Ms. Dickinson spent three years at CoTherix, Inc and was most recently Vice President, Regulatory Affairs and Healthcare Compliance Officer from January 2004 to January 2007. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for CoTherix's initial product, Ventavis® (iloprost) Inhalation Solution. Prior to CoTherix, Inc., Ms. Dickinson held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc. Ms. Dickinson holds a BS in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.


Management - Anthera

investor.anthera.com [cached]

Klara A. Dickinson Senior Vice President and Chief Regulatory Officer Ms. Dickinson served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for Hyperion Therapeutics' initial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid for use as a nitrogen-binding agent for chronic management of adult and pediatric patients ≥2 years of age with urea cycle disorders (UCDs). Prior to Hyperion Therapeutics, Ms. Dickinson spent three years at CoTherix, Inc and was most recently Vice President, Regulatory Affairs and Healthcare Compliance Officer from January 2004 to January 2007. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for CoTherix's initial product, Ventavis® (iloprost) Inhalation Solution. Prior to CoTherix, Inc., Ms. Dickinson held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc. Ms. Dickinson holds a BS in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.


Anthera Pharmaceuticals - Senior Management

www.anthera.com [cached]

Klara A. Dickinson - Senior Vice President and Chief Regulatory Officer

Ms. Dickinson served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for Hyperion Therapeutics' initial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid for use as a nitrogen-binding agent for chronic management of adult and pediatric patients =2 years of age with urea cycle disorders (UCDs). Prior to Hyperion Therapeutics, Ms. Dickinson spent three years at CoTherix, Inc and was most recently Vice President, Regulatory Affairs and Healthcare Compliance Officer from January 2004 to January 2007. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for CoTherix's initial product, Ventavis® (iloprost) Inhalation Solution. Prior to CoTherix, Inc., Ms. Dickinson held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc. Ms. Dickinson holds a BS in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.


Klara Dickinson ...

www.sec.gov [cached]

Klara Dickinson (1)

...
Prior to joining the Company as Senior Vice President, Chief Regulatory Officer on January 5, 2015, Ms. Dickinson provided regulatory consulting service to the Company from October 2014 to December 2014.
...
Klara Dickinson. Ms. Dickinson has served as our Senior Vice President, Chief Regulatory Officer since January 2015.  Prior to that, during 2014, Ms. Dickinson provided regulatory consulting advice to us. Ms. Dickinson served as Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics Inc. from October 2007 to July 2014.  In that role, Ms. Dickinson led the filing of the NDA and label negotiations for Hyperion Therapeutics' initial product, RAVICTI® (glycerol phenylbutyrate) Oral Liquid for chronic management of adult and pediatric patients  more than two years of age with urea cycle disorders (UCDs).   Prior to Hyperion Therapeutics, Ms. Dickinson spent three years at CoTherix, Inc and was most recently Vice President, Regulatory Affairs and Healthcare Compliance Officer from January 2004 to January 2007.  In that role, Ms. Dickinson led the filing of the NDA and label negotiations for CoTherix's initial product, Ventavis ® (iloprost) Inhalation Solution.  Prior to CoTherix, Inc., Ms. Dickinson held various positions at biopharmaceutical companies Scios, Inc. and DEY Laboratories, a subsidiary of Mylan, Inc.  Ms. Dickinson holds a BS in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.


Anthera Pharmaceuticals Inc. ...

www.biocentury.com [cached]

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Business: Autoimmune, Cardiovascular Hired: Klara Dickinson as SVP and chief regulatory officer, formerly SVP of regulatory affairs and compliance at Hyperion …

Similar Profiles

Other People with this Name

Other people with the name Dickinson

Meredith Dickinson
Ifft & Co

Rhoda Dickinson

Ruan Dickinson
KISCH IP

Iryna Dickinson
Beers, Hamerman, Cohen & Burger, P.C.

Luisa Dickinson
Birchwood Conference Centre

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory